tbuckley/cabot-search huggingface dataset:
<i>Helicobacter pylori</i> Eradication Therapy for Nonulcer Dyspepsia
Authors: John M. Bozdech
Journal: Annals of Internal Medicine (2002)

Letters2 April 2002Helicobacter pylori Eradication Therapy for Nonulcer DyspepsiaJohn M. Bozdech, MDJohn M. Bozdech, MDQuincy Medical Group, Quincy, IL 62301Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-7-200204020-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Laine and colleagues (1) have done an admirable job in analyzing published randomized, controlled trials of treatment of H. pylori in patients with nonulcer dyspepsia. They conclude that there is little support for eradication of H. pylori in dyspeptic patients (1). The study by McColl and coworkers (2), however, which was part of their meta-analysis, favors H. pylori eradication therapy and appears to be well designed and well executed. Although there are some methodologic differences between this trial and the three other large studies reported by Laine and colleagues, they do not appear to be enough to ...References1. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;134:361-9. [PMID: 11242496] LinkGoogle Scholar2. McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al . Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 1998;339:1869-74. [PMID: 9862941] CrossrefMedlineGoogle Scholar3. Goel KM, Shanks RA, McAllister TA, Follett EA. Prevalence of intestinal parasitic infestation, salmonellosis, brucellosis, tuberculosis, and hepatitis B among immigrant children in Glasgow. Br Med J. 1977;1:676-9. [PMID: 843867] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Quincy Medical Group, Quincy, IL 62301 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoTherapy for Helicobacter pylori in Patients with Nonulcer Dyspepsia Loren Laine , Philip Schoenfeld , and M. Brian Fennerty Helicobacter pylori Eradication Therapy for Nonulcer Dyspepsia Loren Laine , M. Brian Fennerty , and Philip Schoenfeld Helicobacter pylori Eradication Therapy for Nonulcer Dyspepsia Paul Moayyedi , Jonathan Deeks , and David Forman Helicobacter pylori Eradication Therapy for Nonulcer Dyspepsia Ward B. Buckingham Metrics 2 April 2002Volume 136, Issue 7Page: 555-556KeywordsChildrenDiarrheaGiardiasisHelicobacter pylori ePublished: 2 April 2002 Issue Published: 2 April 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Treating bony metastases.
Authors: C Baughan
Journal: BMJ (1991)

selective damage to specific cell populations has not occurred.Analysis of incorporated bromodeoxyuridine with monoclonal antibodies requires the DNA to be denatured (commonly by exposure to acid).Unfortunately, this step is inherently prone to error as it leads to considerable cell loss and possible damage to antigenic sites.Also, sensitivity to DNA denaturation varies across the cell cycle4for example, cells fixed in late S phase will have more denatured DNA.Our experience in colorectal tumour tissue has shown that labelling indices obtained with both flow cytometry and immunohistochemistry results in reproducible variations that are dependent on acid concentration.The intention of this letter is not to discourage the use of thymidine analogues in cell proliferation analysis but simply to make interested parties aware of the inherent caveats in this methodology.Advances in the clinical application of bromodeoxyuridine will depend on a closer investigation of these enigmas at a tissue specific level.The desire for data should not tempt us to explain the answers before we have asked the questions.
Long-Term Clinical Follow-Up After Successful Repeat Percutaneous Intervention for Stent Restenosis
Authors: Bernhard Reimers, Issam Moussa, Tatsuro Akiyama, Gina Tucci, Massimo Ferraro, Giovanni Martini, Simonetta Blengino, Carlo DI Mario, Antonio Colombo
Journal: Journal of the American College of Cardiology (1997)
Testing Tumor Dormancy in Breast Cancer
Authors: ARON GOLDHIRSCH, RICHARD D. GELBER, MONICA CASTIGLIONE
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Testing Tumor Dormancy in Breast Cancer Get access ARON GOLDHIRSCH, ARON GOLDHIRSCH Search for other works by this author on: Oxford Academic PubMed Google Scholar RICHARD D. GELBER, RICHARD D. GELBER Search for other works by this author on: Oxford Academic PubMed Google Scholar MONICA CASTIGLIONE MONICA CASTIGLIONE Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 7, 6 April 1994, Page 558, https://doi.org/10.1093/jnci/86.7.558 Published: 06 April 1994
No Association of Menopause and Hormone Replacement Therapy With Carotid Artery Intima-Media Thickness
Authors: Azmi A. Nabulsi, Aaron R. Folsom, Moyses Szklo, Alice White, Millicent Higgins, Gerardo Heiss
Journal: Circulation (1996)

Background Cardiovascular disease is the major cause of death in older women. Information on the relation of menopause and hormone replacement therapy with carotid atherosclerosis is limited. Methods and Results We examined cross-sectionally the association of menopausal status, years since last menstruation, and hormone replacement therapy status with carotid artery intima-media thickness as determined by B-mode ultrasound. Female participants (n=5436) in the Atherosclerosis Risk in Communities Study without a history of symptomatic cardiovascular disease were included in the analyses. Menopause status in 45- to 54-year-old women who had never used hormone replacement therapy was not strongly associated with carotid intima-media thickness (mean=0.65 mm and 0.67 mm in premenopausal and postmenopausal women, respectively, adjusted for age, race, cigarette years of smoking, body mass index, sport index, systolic blood pressure, use of blood pressure medications, drinking status, diabetes, and education level). In postmenopausal women aged 55 to 64 years, women with ≤5 years since last menstruation had an adjusted average intima-media thickness (0.74 mm) comparable to those with &gt;5 years since last menstruation (0.75 mm) ( P &gt;.05). Although hormone replacement therapy use was associated with a more favorable lipid and hemostasis profile than nonuse, its use was not associated with intima-media thickness in postmenopausal women aged 55 to 64 years (adjusted average=0.74 mm for current users of estrogen alone and ≈0.75 mm each for current users of estrogen plus progestin, former users, and never users). Conclusions The data suggest that the well-known associations of hormone replacement therapy with reductions in atherosclerotic cardiovascular disease may be attributable more to acute physiological effects, such as hemodynamic changes or reduced thrombosis, than to atherosclerosis itself.
Dietary prevention of ischaemic heart disease--a policy for the '80s.
Authors: B Lewis
Journal: BMJ (1980)

The two daughters of the Greek god of healing, Asklepios, represent contrasting attitudes to medical care: Panacea's name has been translated as Cure-all and Hygieia's as Health. Neither approach alone could overcome the problem of ischaemic heart disease, which led to 156 000 deaths in England and Wales in 1976, proportionately more in Scotland, and much acute and chronic sickness. The valued contributions of coronary care units and of coronary artery surgery in individual management of patients have been estimated to reduce overall mortality from ischaemic heart disease by 4% and (on generous assumptions) 4-5% respectively.12 Medium term trials indicate a place for drug treatment with beta adrenergic blockers,3 and sulphinpyrazone4 and aspirin5 may possibly reduce the risk of reinfarction in patients with ischaemic heart disease. But the need for primary prevention is inescapable.
Maternal and Neonatal Listeriosis: Report of Case and Brief Review of Literature of Listeriosis in Man
Authors: M. Barber, O. A. Okubadejo
Journal: BMJ (1965)

Ethacrynic acid is an effective diuretic in doses ranging from 25 to 450 mg.daily.It is more potent than either organomercurial or benzothiadiazine diuretics.An excessive diuresis may occur after ethacrynic acid, and a test dose is recommended for patients new to the drug.Benzothiadiazines given with ethacrynic acid formed the most potent combination of diuretics tried.Urinary potassium losses are greater after ethacrynic acid than after benzothiadiazines.In resistant cases spironolactone (Aldactone-A) given with ethacrynic acid did not prevent high rates of potassium excretion.Potassium chloride supplements are desirable whenever ethacrynic acid is prescribed, alone or in combination with potassium-sparing agents.The incidence of hypochloraemic hypokalaemic alkalosis is discussed.Agranulocytosis was observed in two patients, but the causal relationship was not established with any certainty.Ethacrynic acid is best used in the treatment of patients with resistant oederna: in such cases we have found it invaluable.
Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy
Authors: Yark Hazewinkel, Thomas de Wijkerslooth, Esther Stoop, Patrick Bossuyt, Katharina Biermann, Marc van de Vijver, Paul Fockens, Monique van Leerdam, Ernst Kuipers, Evelien Dekker
Journal: Endoscopy (2013)

<b>Background and study aims: </b>Serrated polyps of the large intestine comprise a heterogeneous group of lesions with distinct histological and malignant features. The aim of the study was to estimate the prevalence of serrated polyp subtypes in a cohort of individuals undergoing screening colonoscopy, and to identify associations between the detection of serrated polyp subtypes and advanced neoplasia. <b>Patients and methods: </b>Data on serrated polyps, adenomas, and cancers were collected from participants of a randomized screening trial that compared colonoscopy with computed tomography colonography. Only data from participants in the colonoscopy arm were used. Logistic regression analyses were performed to identify associations between patients’ age, sex, and prevalence of the different types of serrated polyps and to identify associations between the detection of these polyps and advanced neoplasia (defined as an adenoma ≥ 10 mm, villous component, high grade dysplasia or colorectal cancer). <b>Results: </b>A total of 1426 screen-naïve individuals (51 % male) with a median age of 60 years (IQR 55 – 65) were included. The prevalence of hyperplastic polyps, sessile serrated adenomas/polyps (SSA/Ps), and traditional serrated adenomas (TSAs) was 23.8 %, 4.8 %, and 0.1 %, respectively. SSA/Ps comprised 7.3 % of all polyps. No differences based on age or sex were observed in the prevalence of SSA/Ps. Proximal and large (≥ 10 mm) hyperplastic polyps, as well as proximal and large (≥ 10 mm) SSA/Ps, were associated with synchronous advanced neoplasia. <b>Conclusions: </b>Serrated polyps, including SSA/Ps, were frequently encountered in routine screening colonoscopies. Large and proximal hyperplastic polyps, as well large and proximal SSA/Ps, were associated with advanced neoplasia.
PPARγ regulates the function of human dendritic cells primarily by altering lipid metabolism
Authors: Istvan Szatmari, Daniel Töröcsik, Maura Agostini, Tibor Nagy, Mark Gurnell, Endre Barta, Krishna Chatterjee, Laszlo Nagy
Journal: Blood (2007)

Abstract Activation of the lipid-regulated nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) modifies the immunophenotype of monocyte-derived dendritic cells (DCs). However it has not been analyzed in a systematic manner how lipid metabolism and immune regulation are connected at the transcriptional level via this receptor. Here we present the genome-wide expression analyses of PPARγ-instructed human DCs. Receptor activation was achieved by exogenous, synthetic as well as endogenous, natural means. More than 1000 transcripts are regulated during DC development by activation of PPARγ; half of the changes are positive effects. These changes appear to enhance and modulate the robust gene expression alterations associated with monocyte to DC transition. Strikingly, only genes related to lipid metabolism are overrepresented among early induced genes. As a net consequence, lipid accumulation appears to be diminished in these cells. In contrast, genes related to immune response are regulated after 24 hours, implying the existence of indirect mechanisms of modulation. Receptor dependence was established by using DCs of patients harboring a dominant-negative mutation of PPARγ. Our data show that PPARγ acts as a mostly positive transcriptional regulator in human developing DCs, acting primarily through controlling genes involved in lipid metabolism and via this, indirectly modifying the immune phenotype.
Modern Medicine and International Aid: Khunde Hospital, Nepal, 1966-1998
Authors: Peter A. Leggat
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P147 Deprivation is associated with increased healthcare utilisation in patients with chronic obstructive pulmonary disease
Authors: P. F. Collins, R. J. Stratton, R. Kurukulaaratchy, M. Elia
Journal: Thorax (2010)

<h3></h3> Deprivation assessed using the index of multiple deprivation (IMD) has been shown to be an independent risk factor for 1-year mortality in outpatients with chronic obstructive pulmonary disease; COPD (Collins <i>et al</i>, 2010). IMD combines a number of economic and social issues (eg, health, education, employment) into one overall deprivation score, the higher the score the higher an individual9s deprivation. Whilst malnutrition in COPD has been linked to increased healthcare use it is not clear if deprivation is also independently associated. This study aimed to investigate the influence of deprivation on 1-year healthcare utilisation in outpatients with COPD. IMD was established in 424 outpatients with COPD according to the geographical location for each patient9s address (postcode) and related to their healthcare use in the year post-date screened (Nobel <i>et al</i>, 2008). Patients were routinely screened in outpatient clinics for malnutrition using the ‘Malnutrition Universal Screening Tool’, ‘MUST’ (Elia 2003); mean age 73 (SD 9.9) years; body mass index 25.8 (SD 6.3) kg/m<sup>2</sup> with healthcare use collected 1 year from screening (Abstract P147 Table 1). Deprivation assessed using IMD (mean 15.9; SD 11.1) was found to be a significant predictor for the frequency and duration of emergency hospital admissions as well as the duration of elective hospital admission. Deprivation was also linked to reduced secondary care outpatient appointment attendance but not an increase in failure to attend and deprivation was not associated with increased disease severity, as classified by the GOLD criteria (p=0.580). COPD outpatients residing in more deprived areas experience increased hospitalisation rates but decreased outpatient appointment attendance. The underlying reason behind this disparity in healthcare use requires further investigation. Collins P.F. <i>et al</i>, (2010) presented at BTS winter meeting (SP165). Stratton RJ, <i>et al</i>, (2003) Disease-related malnutrition, CABI publishing; Elia M (Ed.) (2003) The ‘MUST’ report. BAPEN, Redditch (www.bapen.org.uk); Nobel <i>et al</i>, (2008) The English indices of deprivation 2007 (www.communities.gov.uk).
Clinical and Laboratory Manifestations of Toxic Shock Syndrome
Authors: ROBERT W. TOFTE
Journal: Annals of Internal Medicine (1982)

We studied 28 women and two men, with a median age of 20 years, who first had toxic shock syndrome between 1 February 1980 and 15 July 1981. Two of these patients died. All patients had intense myalgia, high fever (greater than or equal to 38.9 degrees C), hypotension or syncope, skin rash and desquamation, and abnormalities in at least three organ systems. Over half had sterile pyuria; immature granulocytic leukocytosis; coagulation abnormalities; hypocalcemia; low serum albumin and total protein concentrations; and elevations of blood urea nitrogen, alanine transaminase, bilirubin, and creatine kinase. Staphylococcus aureus was isolated from cultures from sites of soft-tissue infection in both male patients and from 13 of 19 vaginal and eight of 12 cervical cultures. All isolates produced both pyrogenic exotoxin C and enterotoxin F. All patients with a febrile, exanthematous, multisystem illness, particularly one associated with menstruation or a staphylococcal infection, should be promptly evaluated and empirically treated for toxic shock syndrome.
Disseminated Intravascular Coagulation with the Peritoneovenous Shunt
Authors: DAVID C. HARMON
Journal: Annals of Internal Medicine (1979)

Coagulation data were collected before and after peritoneovenous shunting for intractable ascites in 19 shunting procedures. After insertion of the shunts, changes consistent with disseminated intravascular coagulation developed in all cases in which good flow of ascitic fluid was obtained. In cases with temporary shunt function, the coagulation variables suggestive of disseminated intravascular coagulation returned toward normal when the flow of ascitic fluid ceased. A fall in the level of fibrinogen degradation products indicated that the shunt had clotted. Bleeding attributable to disseminated intravascular coagulation alone was uncommon. Clotting of the shunts was frequent. The use of heparin improved some of the coagulation variables but did not prevent shunt clotting or clinical bleeding. We conclude that the peritoneovenous shunt induces a moderate disseminated intravascular coagulation and that measurement of fibrinogen degradation products is useful in assessing shunt function.
Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis.
Authors: E J Denman, A M Denman, B M Greenwood, D Gall, R B Heath
Journal: Annals of the Rheumatic Diseases (1970)

Classical rheumatoid arthritis by criteria of American Rheumatism Association (1958) Still's disease by criteria of Ansell and Bywaters (1959) C = Chlorambucil A = Azathioprine *Platelets < 100,000/cu.mm.Neutrophils < 1,000/cu.mm.Haemoglobin < 8 g. per cent. DOSAGE OF CYTOTOXIC DRUGSnumber of patients on each drug was small.Azathioprine (Imuran) and chlorambucil were used initially in a dose of 2 5 mg./kg.bodyweight and 0 01 PLAN OF IMMUNOLOGICAL ASSESSMENT mg./kg.bodyweight respectively.The dosage was sub-Patients receiving cytotoxic drugs (Group A) sequently adjusted to maintain a persistent lymphopenia; Immunological responses were measured before, during, details of treatment are given in Table I.The results of and after treatment with cytotoxic drugs (Table III, treatment with both drugs are considered together as the overleaf).
Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C
Authors: Ray W. Kim, John J. Poterucha
Journal: Hepatology (2000)

In their paper in the November issue of HEPATOLOGY, Younossi et al. 1 may have overestimated the cost effectiveness of interferon-ribavirin treatment.This mainly stems from their failure to take into account the fact that patients who achieve sustained response are not homogenous with respect to their risk of development of decompensated liver disease.Some of the predictive factors that are associated with higher response rate after interferon-ribavirin combination therapy as reported by Poynard et al., 2 including genotype, viral load, age, and fibrosis, have also been associated with a better prognosis in natural history studies. 3,4 Thus, patients who respond to therapy tend to have a lower risk of developing cirrhosis and its complications.Ignoring this overlap of predictive factors would lead to an overestimation of the costeffectiveness of antiviral treatment.The relevance of this point is illustrated by the difference in the results between the study by Younossi et al. and our previous analysis. 5 In their Table 5, the authors reported that interferon monotherapy for 48 weeks was cost-saving.In other words, the cost of interferon treatment up front was more than compensated for by the reduction in future costs incurred by later complications of chronic liver disease.This is in contrast to our analysis in which interferon therapy increased the overall cost, although its cost-effectiveness remained within a reasonable range in comparison with other medical interventions.The methods used in both analyses were essentially identical including the response rate, discount rate, and the rate for discontinuing the treatment at 3 months in initial nonresponders.The only significant difference was that Younossi et al. did not incorporate the fact that responders to interferon therapy would be less likely to develop liver problems in the future.Instead, they assumed that patients with chronic hepatitis C would progress to cirrhosis at a uniform rate of 7.3% per year.This was based on a study by Yano et al., 6 in which the rate of histological progression was assessed in sequential biopsies in patients with suspected progressive disease.These assumptions predispose the model to an inherent bias in favor of benefits of antiviral therapy, including not only interferon monotherapy but also the combination of interferon and ribavirin.Given the relatively high cost per quality-adjusted life year (QALY) figures reported by the authors (over $37,000), an unbiased estimate of the cost-effectiveness of combination therapy may in fact approach the arbitrary but widely accepted limit of $50,000 per QALY gained.